BioXcel Therapeutics/BTAI

$1.84

2.79%
-
1D1W1MYTD1YMAX

About BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Ticker

BTAI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Vimal Mehta

Employees

74

Headquarters

New haven, United States

BTAI Metrics

BasicAdvanced
$70M
Market cap
-
P/E ratio
-$5.18
EPS
0.35
Beta
-
Dividend rate
$70M
0.35156
$22.06
$1.79
549K
2.57
2.493
-15.67%
-116.64%
-151.39%
39.754
202.24%
21.9%

What the Analysts think about BTAI

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
348.37% upside
High $18.00
Low $3.50
$1.84
Current price
$8.25
Average price target

BTAI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,340% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
66.67%
Net income
-$27M
20.27%
Profit margin
-5,340%
-27.84%

BTAI Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 24.58%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.83
-$1.72
-$0.76
-$0.87
-
Expected
-$1.75
-$1.30
-$0.91
-$0.70
-$0.71
Surprise
4.52%
31.9%
-16.48%
24.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for BioXcel Therapeutics stock?

BioXcel Therapeutics (BTAI) has a market cap of $70M as of May 30, 2024.

What is the P/E ratio for BioXcel Therapeutics stock?

The price to earnings (P/E) ratio for BioXcel Therapeutics (BTAI) stock is 0 as of May 30, 2024.

Does BioXcel Therapeutics stock pay dividends?

No, BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next BioXcel Therapeutics dividend payment date?

BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders.

What is the beta indicator for BioXcel Therapeutics?

BioXcel Therapeutics (BTAI) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the BioXcel Therapeutics stock price target?

The target price for BioXcel Therapeutics (BTAI) stock is $8.25, which is 348.37% above the current price of $1.84. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell BioXcel Therapeutics stock

Buy or sell BioXcel Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing